About Alghorismus

Clinical questions.
Computational investigation.

Alghorismus is a data science company focused on machine learning research for cancer treatment-response stratification.

Our purpose

Study the variation
behind treatment response.

The original Alghorismus vision centers on integrating molecular profiles, clinical characteristics, and treatment outcomes to investigate why patients respond differently to therapy.

The long-term aim is better evidence for treatment-response research, trial development, and informed clinical investigation. Translating that aim into patient care requires further validation.

Scientific leadership

Fahad S. Ahmed, MD

Founder & Chief Scientist

Physician-scientist working at the intersection of pathology, biomarkers, and machine learning.

Contact Alghorismus

The original vision, carried forward

Three questions guide the work.

Can additional evidence help identify potential treatment responders?
Can research identify groups that warrant evaluation of alternative therapeutic approaches or clinical trials?
Can better characterization of uncertainty improve scientific and clinical conversations?

Sources & further reading

2023 Immuno-Oncology Summit: speaker and session record

Read the original website text Historical record

Original wording retained for transparency. Dates, claims, and figures below reflect the earlier website; the interpretation above explains current limitations.

Alghorismus

Machine learning algorithms for patient stratification

Alghorismus is a data science company dedicated to revolutionizing cancer treatment through the power of machine learning. Leveraging cutting-edge data analytics and artificial intelligence, the company specializes in predicting individual patient responses to immunotherapies in the battle against cancer. By analyzing vast amounts of patient data, including multi-omics profiles, clinical records, and treatment outcomes, their advanced machine-learning models can identify patients who will respond to treatment and correlate with treatment effectiveness. Through their innovative approach, Alghorismus aims to significantly enhance the precision and success rates of immunotherapies, ultimately bringing new hope to patients and advancing the field of oncology.

Our vision for our machine learning models is that they will play a pivotal role in predicting patient treatment response in advanced urothelial, melanomas, and breast cancers in both research and clinical settings. We hope to create an impact in the following areas:

Potential responders can receive treatment faster, these patients can decide to use our prediction as a data point to make treatment decisions.
Potential non-responders can be enrolled in a clinical trial with either a same-class newer agent (as a treatment-naive patient) or a different-class newer agent.
Clinicians can use the results to better inform the patient about what treatment with immunotherapy may look like in the next few months and years.

Start a scientific conversation